Calidi Biotherapeutics, Inc. (CLDI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.27. The rating moved from Neutral to Oversold on August 18, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$1.27
• Last changeMoved from Neutral to Oversold on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Calidi Biotherapeutics is a small, development-focused biopharma with upside driven primarily by pipeline progress and partnership/licensing outcomes. The company likely lacks material revenue and depends on capital markets or deals to fund development, creating meaningful dilution and execution risk. Market sentiment toward small-cap biotech is currently constructive, which may provide episodic support for the share price around clinical or corporate news. Key near-term sensitivities are cash runway, financing cadence, and any program-specific announcements; absent clear near-term positive catalysts, the share price is best viewed as high-volatility, event-driven exposure.

Key factors

• Early-stage biopharma profile with limited public financial disclosures and likely negative operating cash flow typical of clinical-stage companies
• Pipeline and platform potential (preclinical/clinical assets) that could generate significant valuation upside on positive clinical readouts or partnerships
• High dependence on external financing or partnership transactions to fund operations and advance programs
• Sector-wide investor sentiment is mildly risk-on, which can provide short-term support for small-cap biotech names
• Potential for M&A or licensing interest from larger biopharma if programs demonstrate differentiation or addressable market opportunity

Risks

• Clinical or development setbacks that could materially reduce valuation
• Cash runway limitations and need for dilutive financing (secondary offerings, convertible instruments)
• Regulatory approval risk and lengthy development timelines
• Low daily trading liquidity increasing price volatility and bid/ask spreads
• Competitive threats from better-capitalized peers or alternative therapeutic approaches
• Macro/market volatility (rates, risk appetite) that can disproportionately hurt small biotech stocks

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.